Lupus Nephritis Clinical Trials in Wuhan, Hubei
8 recruitingWuhan, Hubei, China
Showing 1–8 of 8 trials
Recruiting
Phase 2
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Lupus Nephritis
Novartis Pharmaceuticals240 enrolled103 locationsNCT05268289
Recruiting
Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Lupus Nephritis
Novartis Pharmaceuticals462 enrolled188 locationsNCT05126277
Recruiting
Phase 3
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Lupus Nephritis
Novartis Pharmaceuticals315 enrolled25 locationsNCT06711887
Recruiting
Phase 1Phase 2
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
Lupus Nephritis
Nanjing Immunophage Biotech Co., Ltd36 enrolled17 locationsNCT06717815
Recruiting
Not Applicable
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Tongji Hospital6 enrolled1 locationNCT06902844
Recruiting
Early Phase 1
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
IgG4-related DiseaseLupus Nephritis
Tongji Hospital30 enrolled1 locationNCT06497387
Recruiting
Early Phase 1
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
IgG4-related DiseaseLupus Nephritis
Tongji Hospital30 enrolled1 locationNCT06497361
Recruiting
Not Applicable
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Lupus Nephritis
Lingli Dong24 enrolled1 locationNCT06277427